Matinas BioPharma Holdings, Inc. - MTNB STOCK NEWS

Matinas BioPharma Holdings (MTNB) announced a Special Meeting of Stockholders on January 26, 2021, to seek approval for a potential reverse stock split of its common stock, within a range of 1-for-2 to 1-for-15. This initiative aims to enhance the stock's appeal to institutional investors and possibly facilitate inclusion in biotechnology and pharmaceutical indices, while positioning the company for an uplisting to major exchanges like NYSE or NASDAQ. The final split ratio will be determined by the Board after stockholder approval.

Matinas BioPharma Holdings, Inc. (MTNB) has appointed Hui Liu, Ph.D., M.B.A. as the new Chief Technology Officer. With over 20 years of experience in pharmaceutical development, particularly in lipid-based delivery systems, Dr. Liu aims to enhance the company's proprietary lipid nanocrystal (LNC) platform. Previously at Seqirus, he has expertise in lipid nanoparticle technologies for gene therapies. The company continues to advance its lead product, MAT9001, targeting hypertriglyceridemia, and is also developing MAT2203 and MAT2501 for serious infections and antibiotic treatments, respectively.

Matinas BioPharma (MTNB) has secured an award of up to $3.75 million from the Cystic Fibrosis Foundation to support the preclinical development of MAT2501, an oral formulation of amikacin targeting nontuberculous mycobacterial lung disease. The funding aims to accelerate MAT2501's advancement through essential studies towards Phase 2 trials. FDA designations as QIDP and Orphan Drug for MAT2501 offer potential marketing exclusivity for up to 12 years upon approval. The company is focused on addressing unmet medical needs in the treatment of chronic infections.

Matinas BioPharma Holdings, Inc. (NYSE: MTNB) will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3, 2020. The company is set to host investor meetings and will have a pre-recorded fireside chat available on their website starting November 23, 2020. Matinas is focused on developing therapeutics for unmet medical needs, with its lead product candidate, MAT9001, targeting hypertriglyceridemia. Additionally, MAT2203, aimed at treating invasive fungal infections, is currently in a Phase 2 study for HIV-infected patients.

Matinas BioPharma Holdings (NYSE: MTNB) reported progress in its clinical studies and financial results for Q3 2020. The EnACT study of MAT2203 for cryptococcal meningitis received a recommendation from the DSMB to proceed to the second cohort, with evaluations set for mid-2021. Enrollment in the ENHANCE-IT study of MAT9001 against Vascepa is complete, and topline data is expected in Q1 2021. The company ended the quarter with $62.8 million in cash and a net loss of $5.7 million. Management remains focused on advancing its drug candidates and anticipates sufficient funds for operations through H1 2023.

Matinas BioPharma Holdings (MTNB) will host a conference call and live webcast on November 6, 2020, at 8:30 a.m. ET, to discuss Q3 2020 operational and financial results. Interested participants can join via phone or through the Investors section of the Matinas website, where the event will also be archived for 90 days. The company, focused on next-generation therapeutics, is developing MAT9001 for hypertriglyceridemia and MAT2203 for invasive fungal infections. Topline data for MAT9001 is expected in Q1 2021, while MAT2203 is in a Phase 2 study.

Matinas BioPharma (MTNB) has received a unanimous recommendation from the Data and Safety Monitoring Board (DSMB) to progress to the second cohort of its EnACT study for MAT2203, an oral formulation of amphotericin B aimed at treating cryptococcal meningitis. Enrollment for the 40 patient cohort will begin soon, with the next DSMB review expected in mid-2021. MAT2203 has also been designated as a Qualified Infectious Disease Product and has Fast Track status from the FDA, enhancing its potential for addressing significant unmet medical needs.

Matinas BioPharma (MTNB) announced positive outcomes from its End of Phase 2 meeting with the FDA regarding MAT9001, an omega-3 therapy for severe hypertriglyceridemia (SHTG). The FDA agreed on the requirement for a single Phase 3 trial lasting 12 weeks, which will support a New Drug Application (NDA). Matinas aims to initiate this Phase 3 program in the first half of 2021. The alignment with FDA provides clarity for the registration pathway and the company anticipates upcoming data from its ENHANCE-IT trial against Vascepa, potentially differentiating MAT9001 and underscoring its clinical benefits.

Matinas BioPharma Holdings, Inc. (MTNB) has appointed Natasha Giordano as an independent director effective September 14, 2020. With over 25 years in healthcare leadership, her expertise will strengthen the board as the company advances its clinical development. Current board member Adam Stern will transition to a consulting role after the Annual Meeting of Stockholders on November 2, 2020, having served since the company's inception. The changes are seen as strategic moves to enhance shareholder value and support upcoming product milestones.